Trial Profile
Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Aug 2020
Price :
$35
*
At a glance
- Drugs Piperacillin/tazobactam (Primary)
- Indications Bacterial infections; Nosocomial infections
- Focus Pharmacokinetics
- 04 May 2018 Status changed from recruiting to completed.
- 04 Dec 2014 Planned End Date changed from 1 Jul 2013 to 1 Jul 2015 as reported by ClinicalTrials.gov.
- 04 Dec 2014 Planned primary completion date changed from 1 Jul 2013 to 1 Jul 2015 as reported by ClinicalTrials.gov.